Side CAR-T® delivery system
Lupagen avoids the cost & complexity of ex vivo cell therapy and the biodistribution & immunogenicity challenges of in vivo gene therapy by a simple patient-connected procedure done at the bedside.
Our Side CAR-T® delivery system, a first-in-class bedside system enables cell & gene therapy delivery directly to target cells in a highly-controlled and safe environment before reinfusing therapies to the patient in a simple out-patient procedure, resulting in significantly lower treatment burden and cost.
“Best of Breed” Nanoparticle Gene Delivery Platform
Lupagen is developing nanoparticle-based gene therapies internally and in partnership with select biopharma companies that can be delivered using our Side CAR-T® delivery system and accommodate a wide range of payloads & gene editing systems resulting in safer, more effective gene therapy.
Nanoparticle platforms, widely used to deliver RNA and DNA, can be delivered elegantly to targeted peripheral blood mononuclear cell populations to generate cell & gene therapies addressing oncology, autoimmune and other indications.
Lupagen’s flexible platform agnostic development approach combined with our proprietary bedside delivery system results in:
Broader array of targets and indications that can be developed
Ability to leverage a wide range of nanoparticles systems (lipid, polymer, coated virus)
SAFER and MORE EFFECTIVE targeted delivery of nanoparticles than can be achieved in-vivo by avoiding current systemic toxicity and dosing challenges